О ВОЗМОЖНОСТЯХ ОСЛАБЛЕНИЯ ИНТЕНСИВНОСТИ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ У БОЛЬНЫХ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА РЕЗОЛЮЦИЯ СОВЕТА ЭКСПЕРТОВ ОБЩЕСТВА СПЕЦИАЛИСТОВ ПО НЕОТЛОЖНОЙ КАРДИОЛОГИИ
https://doi.org/10.21518/2307-1109-2018-1-67-69
Аннотация
Дата проведения: 25 октября 2017 г.
Список литературы
1. Levine GN, Bates ER, Bittl JA et al. 2016 ACC / AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease: A Report of the American College of Cardiology / American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol, 2016, 68: 1082–1115.
2. Ibanez B, James S, Agewall S et al., ESC Scientific Document Group. 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J, 2018, 39: 119–177.
3. Ro M, Patrono C, Collet JP et al. Management of Acute Coronary Syndromes in Patients Presenting without Persistent STSegment Elevation of the European Society of Cardiology. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J, 2016, 37: 267–315.
4. Valgimigli M, Bueno H, Byrne RA et al., ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J, 2017, doi: 10.1093/eurheartj/ehx419.[Epub ahead of print].
5. Cuisset T, Deharo P, Quilici J et al. Benefit of switching dual antiplatelet therapy after acute coronary syndrome: the TOPIC (timing of platelet inhibition after acute coronary syndrome) randomized study. Eur Heart J 2017; 38:3070–3078.
6. Sibbing D, Aradi D, Jacobshagen C et al., TROPICAL-ACS Investigators. A randomised trial on platelet function-guided de-escalation of antiplatelet treatment in ACS patients undergoing PCI. Rationale and design of the Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment for Acute Coronary Syndromes (TROPICAL-ACS) Trial. Thromb Haemost, 2017, 117: 188–195.
Рецензия
Для цитирования:
О ВОЗМОЖНОСТЯХ ОСЛАБЛЕНИЯ ИНТЕНСИВНОСТИ АНТИТРОМБОЦИТАРНОЙ ТЕРАПИИ У БОЛЬНЫХ ПОСЛЕ ОСТРОГО КОРОНАРНОГО СИНДРОМА РЕЗОЛЮЦИЯ СОВЕТА ЭКСПЕРТОВ ОБЩЕСТВА СПЕЦИАЛИСТОВ ПО НЕОТЛОЖНОЙ КАРДИОЛОГИИ. Атеротромбоз. 2018;(1):67-69. https://doi.org/10.21518/2307-1109-2018-1-67-69
For citation:
ON THE POSSIBILITIES OF ATTENUATION OF ANTIPLATELET THERAPY INTENSITY IN PATIENTS AFTER ACUTE CORONARY SYNDROME. RESOLUTION OF THE PANEL OF EXPERTS OF THE EMERGENCY CARDIOLOGY SOCIETY. Aterotromboz = Atherothrombosis. 2018;(1):67-69. (In Russ.) https://doi.org/10.21518/2307-1109-2018-1-67-69
Просмотров: 691
Контент доступен под лицензией Creative Commons Attribution Attribution-NonCommercial-NoDerivs License.
Послать статью по эл. почте 